The development of catheter-based interventions has revolutionized the treatment of coronary artery disease (CAD), from the first heart catheterization in 1929 to the emergence of drug-coated balloons (DCBs) as a treatment for in-stent restenosis (ISR). This review explores the evolution and clinical application of DCBs in CAD, with a particular focus on their role in managing ISR, de novo coronary disease, and complex lesions. DCBs deliver antiproliferative drugs such as paclitaxel or sirolimus to the vessel wall and have emerged as a promising alternative to traditional stent-based therapies, reducing the need for permanent metallic implants and associated thrombotic risks. Early research demonstrated the effectiveness of DCBs in ISR, and recent studies have expanded their application to small vessel disease, bifurcation lesions, and long diffuse lesions. Notably, DCBs have shown non-inferiority to drug-eluting stents in certain cases, including high-risk patients and those with complex coronary anatomy. Despite some challenges, such as the potential for coronary dissection and the need for optimal lesion preparation, DCBs have demonstrated strong potential in reducing restenosis and improving long-term outcomes in a variety of patient populations. While further studies are required to refine their use in off-label indications, DCBs may represent a versatile, effective, and safer approach in the management of CAD.
As transcatheter tricuspid valve replacement with the EVOQUE system gains wider clinical adoption, growing experience has highlighted key anatomical considerations that influence procedural success. While right transfemoral (TF) access is the standard approach, it can be technically challenging in patients with complex right heart anatomy, such as low right atrium (RA) height or a large inferior vena cava–tricuspid valve annulus (IVC-TVA) offset. These factors may lead to suboptimal trajectory, impaired coaxiality, and difficult valve deployment. Left TF access offers a potential alternative by providing additional RA height and a more favorable lateral trajectory, allowing improved alignment with the tricuspid valve annulus (TVA). This approach is particularly useful in patients with large short-axis (SAX) offsets (>20 mm) or steep long-axis angles where right TF access may not achieve perpendicular orientation despite secondary catheter flexion. Using a preprocedural cardiac computed tomography angiography (CCTA) scan, anatomical factors such as RAH, leaflet tethering height, RV depth, and papillary muscle location can be evaluated to guide access planning. While left TF access introduces its own technical considerations, including venous tortuosity, excessive unwanted RA height, and increased need for primary flex, it may expand procedural feasibility in anatomically challenging cases. This review outlines real-world scenarios where left-sided access was favored, supporting its use as a safe and effective strategy in selected patients. Further studies are warranted to assess long-term outcomes and to inform the design of next-generation delivery systems capable of accommodating broader anatomical variation.
8 June 2025 in Catheterization and Cardiovascular Interventions
Increasing recognition of the clinical impact of isolated tricuspid regurgitation has led to rapid expansion of surgical and transcatheter tricuspid valve interventions. Given the close anatomic relationship between the tricuspid valve and the atrioventricular conduction system, both surgical and transcatheter approaches carry a significant risk of new conduction disturbances and permanent pacemaker implantation. A three-dimensional understanding of the atrioventricular conduction axis is essential to anticipate and mitigate these complications. This review provides a comprehensive overview of conduction system anatomy and physiology in the context of tricuspid valve interventions, highlighting the mechanisms underlying procedure-related conduction abnormalities. We also discuss contemporary management strategies, including approaches to pre-existing transvalvular leads, valve-sparing pacing alternatives, and the evolving role of electrophysiologists within the multidisciplinary heart team.
This meta-analysis aims to compare chest compression-only cardiopulmonary resuscitation (CO-CPR) with standard CPR (sCPR), which includes mouth-to-mouth ventilation, as potential strategies for managing out-of-hospital cardiac arrest (OHCA). We systematically searched various databases and registries such as MEDLINE, Embase, The Cochrane Library, and Clinicaltrials.gov to retrieve relevant studies. We used the revised Cochrane “Risk of Bias” tool for randomized trials (RoB 2.0) to assess the risk of bias in included studies. Revman 5.4 was used to pool dichotomous outcomes under a random effects model. A total of 4 randomized controlled trials were included in our meta-analysis. Our results indicate that CO-CPR was associated with a significantly increased survival to hospital discharge compared to sCPR [relative risk (RR) 1.22, 95% confidence interval (CI): 1.01 to 1.46] with minimal heterogeneity (I2=0%). No significant difference was observed between the two groups regarding 1-day survival (RR 1.07, 95% CI: 0.94 to 1.23), survival to hospital admission with a good neurological outcome (cerebral performance category 1 or 2) (RR 1.10, 95% CI: 0.80 to 1.51), return of spontaneous circulation (RR 1.05, 95% CI: 0.95 to 1.17), and survival to hospital admission (RR 1.08, 95% CI: 0.93 to 1.25). This meta-analysis found that chest CO-CPR significantly improves survival to hospital discharge compared to sCPR for managing OHCA, while yielding comparable results for other resuscitation outcomes.